Top Markets
Coin of the day
Relmada Therapeutics, Inc. Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Rang in Aktien #13828
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company... Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Aktienkurs
$4.36
Marktkapitalisierung
$457.32M
Veränderung (1 Tag)
0.69%
Veränderung (1 Jahr)
289.29%
Land
US
Handel Relmada Therapeutics, Inc. (RLMD)

Kategorie

Kursverlauf für Relmada Therapeutics, Inc. (RLMD)
Höchster Schlusskurs: $4.68 am 2026-08-01

Niedrigster Schlusskurs: $11.43 am 2014-06-01
Kursverlauf der Aktie von Relmada Therapeutics, Inc. von 2014 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 10.22%
2025 860.47%
2024 -36.35%
2023 -17.50%
2022 -78.37%
2021 -41.31%
2020 -14.84%
2019 756.21%
2018 52.34%
2017 -6.63%
2016 -71.17%
2015 -80.90%
2014 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.01 -13.08%
AU
$138.80 476.17%
US
$749.90 5.87%
CH